|
Ann Arbor, MI – February 22, 2007
– Compendia Bioscience, Inc.™,
the leading provider of cancer profiling data
and analysis tools, and Ingenuity Systems®,
the leading provider of software and data
bases for biological exploration, interpretation,
and analysis, today announced the integration
of their flagship products Oncomine™
Professional and Ingenuity Pathways Analysis.
These newly integrated products will allow
users to navigate directly from cancer gene
signatures discovered in Oncomine Professional
to the curated pathway information available
from Ingenuity Pathways Analysis (IPA).
Oncomine Professional is a rapidly growing
compendium of transcriptome profiles coupled
with analysis functions and a web application
for data mining and visualization. Comprised
of thousands of profiles representing every
major type of cancer, Oncomine Professional
was developed to exploit this data for therapeutic
target discovery, validation, and prioritization.
Ingenuity Pathways Analysis is a software
application that enables biologists and bioinformaticians
to identify the biological mechanisms, pathways,
and functions most relevant to their experimental
datasets or genes of interest.
“In recent years, we have witnessed
an explosion of genome-scale cancer profiling.
Known types and subtypes of cancer can now
be distinguished by their gene expression
patterns,” said Matt Anstett, Vice President
of Scientific Applications at Compendia Bioscience.
“Our goal is to maximize the usefulness
of this information, by providing users with
the tools they need to interpret gene signatures
in biologically meaningful terms. Integrating
Compendia’s cancer gene signatures with
Ingenuity’s pathway analysis goes a
long way towards accomplishing that goal.”
“I am enthusiastic about the integration
between Ingenuity Pathways Analysis and Compendia’s
Oncomine Professional, as it will expedite
discoveries in the field of cancer research,”
continued Tuan Nguyen, Vice President, Partner
and Professional Services. “An integrated
workflow based on IPA’s capabilities
for rapid and reliable biological interpretation
of Compendia’s high quality cancer transcriptome
profiles provides a powerful and complete
solution to oncology researchers focused on
understanding mechanisms of disease, and on
the discovery and validation of cancer biomarkers.”
About Compendia Bioscience, Inc.™
Compendia Bioscience is dedicated to harnessing
the global collection of high throughput molecular
data to provide researchers with the data
and analysis tools necessary to validate biomarker
and gene target discoveries, better understand
mechanisms of disease, and optimize clinical
studies. Compendia’s first product,
Oncomine™ Professional, empowers oncology
research by bringing advanced data analysis
tools to the world’s largest cancer
gene expression database, which now includes
data from 18,740 microarray experiments curated
from 264 independent studies. Oncomine was
originally developed for academic use at the
University of Michigan, and continues to be
freely available to academic users. Compendia
Bioscience was founded in 2006 to extend Oncomine
to the commercial sector, and is headquartered
in Ann Arbor, Michigan. www.compendiabio.com.
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze
and understand complex biological systems
foundational to human health and disease.
The Ingenuity products include pathways analysis
software and knowledge bases for biologists
and bioinformaticians, and enterprise knowledge
management infrastructure, content and services
for leading pharmaceutical and biotech companies.
Ingenuity was founded in 1998 and is headquartered
in Redwood City, California with offices in
Germany, Switzerland, France, the United Kingdom,
and Japan. www.ingenuity.com.
For additional information regarding
this announcement, please contact:
Matt Anstett
VP Scientific Applications
Compendia Bioscience, Inc.
Email: manstett@compendiabio.com
Heidi Bullock
Director, Marketing
Ingenuity Systems
650.381.5150
>
View as PDF 
|
